609 related articles for article (PubMed ID: 17372866)
1. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability.
Madgula VL; Avula B; Reddy V L N; Khan IA; Khan SI
Planta Med; 2007 Apr; 73(4):330-5. PubMed ID: 17372866
[TBL] [Abstract][Full Text] [Related]
2. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
3. Decursinol angelate: a cytotoxic and protein kinase C activating agent from the root of Angelica gigas.
Ahn KS; Sim WS; Lee IK; Seu YB; Kim IH
Planta Med; 1997 Aug; 63(4):360-1. PubMed ID: 9270380
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
Wang Q; Rager JD; Weinstein K; Kardos PS; Dobson GL; Li J; Hidalgo IJ
Int J Pharm; 2005 Jan; 288(2):349-59. PubMed ID: 15620875
[TBL] [Abstract][Full Text] [Related]
5. Transport of parthenolide across human intestinal cells (Caco-2).
Khan SI; Abourashed EA; Khan IA; Walker LA
Planta Med; 2003 Nov; 69(11):1009-12. PubMed ID: 14735438
[TBL] [Abstract][Full Text] [Related]
6. Role of 99mTc-mannitol and 99mTc-PEG in the assessment of paracellular integrity of cell monolayers.
Shah PJ; Jogani VV; Mishra P; Mishra AK; Bagchi T; Misra AR
Nucl Med Commun; 2007 Aug; 28(8):653-9. PubMed ID: 17625388
[TBL] [Abstract][Full Text] [Related]
7. Decursin and decursinol angelate selectively inhibit NADH-fumarate reductase of Ascaris suum.
Shiomi K; Hatano H; Morimoto H; Ui H; Sakamoto K; Kita K; Tomoda H; Lee EW; Heo TR; Kawagishi H; Omura S
Planta Med; 2007 Nov; 73(14):1478-81. PubMed ID: 17948169
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
Mahat B; Chae JW; Baek IH; Song GY; Song JS; Ma JY; Kwon KI
Drug Dev Ind Pharm; 2013 Oct; 39(10):1523-30. PubMed ID: 23003006
[TBL] [Abstract][Full Text] [Related]
9. Intestinal permeability of the constituents from the roots of Saposhnikovia divaricata in the human Caco-2 cell monolayer model.
Zhao B; Yang XB; Yang XW; Wu Q; Wang Y; Zhang LX; Xu W
Planta Med; 2011 Sep; 77(13):1531-5. PubMed ID: 21308612
[TBL] [Abstract][Full Text] [Related]
10. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
[TBL] [Abstract][Full Text] [Related]
11. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas.
Ahn KS; Sim WS; Kim IH
Planta Med; 1996 Feb; 62(1):7-9. PubMed ID: 8720379
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes.
Abd El-Aty AM; Shah SS; Kim BM; Choi JH; Cho HJ; Hee-Yi ; Chang BJ; Shin HC; Lee KB; Shimoda M; Shim JH
Arch Pharm Res; 2008 Nov; 31(11):1425-35. PubMed ID: 19023539
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Hu HH; Bian YC; Liu Y; Sheng R; Jiang HD; Yu LS; Hu YZ; Zeng S
Int J Pharm; 2014 Jan; 460(1-2):101-7. PubMed ID: 24262988
[TBL] [Abstract][Full Text] [Related]
14. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase.
Son SH; Kim MJ; Chung WY; Son JA; Kim YS; Kim YC; Kang SS; Lee SK; Park KK
Cancer Lett; 2009 Jul; 280(1):86-92. PubMed ID: 19307054
[TBL] [Abstract][Full Text] [Related]
15. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening.
Irvine JD; Takahashi L; Lockhart K; Cheong J; Tolan JW; Selick HE; Grove JR
J Pharm Sci; 1999 Jan; 88(1):28-33. PubMed ID: 9874698
[TBL] [Abstract][Full Text] [Related]
16. In vitro models for the blood-brain barrier.
Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
[TBL] [Abstract][Full Text] [Related]
17. Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC.
Li L; Zhang J; Shaik AA; Zhang Y; Wang L; Xing C; Kim SH; Lü J
Planta Med; 2012 Feb; 78(3):252-9. PubMed ID: 22116603
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats.
Song JS; Chae JW; Lee KR; Lee BH; Choi EJ; Ahn SH; Kwon KI; Bae MA
Xenobiotica; 2011 Oct; 41(10):895-902. PubMed ID: 21657833
[TBL] [Abstract][Full Text] [Related]
19. Transport of hop bitter acids across intestinal Caco-2 cell monolayers.
Cattoor K; Bracke M; Deforce D; De Keukeleire D; Heyerick A
J Agric Food Chem; 2010 Apr; 58(7):4132-40. PubMed ID: 20329731
[TBL] [Abstract][Full Text] [Related]
20. [Absorption of papaverine, laudanosine and cepharanthine across human intestine by using human Caco-2 cells monolayers model].
Ma L; Yang XW
Yao Xue Xue Bao; 2008 Feb; 43(2):202-7. PubMed ID: 18507350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
